Shape Therapeutics, Inc. Raises $35.5M Series A Financing, Led by NEA and Announces the Formation of a World-Class Scientific Advisory Board, to Advance a First-in-Class RNA Editing Gene Therapy Platform Focused on Curing Genetic Diseases
Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative
HIV Eliminated from the Genomes of Living Animals; Excision BioTherapeutics Advancing the Innovation to Clinical Development
